UY29711A1 - SMALL AGONISTS AND THEIR USES - Google Patents

SMALL AGONISTS AND THEIR USES

Info

Publication number
UY29711A1
UY29711A1 UY29711A UY29711A UY29711A1 UY 29711 A1 UY29711 A1 UY 29711A1 UY 29711 A UY29711 A UY 29711A UY 29711 A UY29711 A UY 29711A UY 29711 A1 UY29711 A1 UY 29711A1
Authority
UY
Uruguay
Prior art keywords
agonists
small
small agonists
pyy3
npy
Prior art date
Application number
UY29711A
Other languages
Spanish (es)
Inventor
Nancy Ann Nardone
Ned Roger Siegel
Rory Francis Finn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW095103474A external-priority patent/TWI310038B/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY29711A1 publication Critical patent/UY29711A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona variantes del péptido PYY3-36 y sus derivados pegilados y composiciones y métodos útiles en el tratamiento de estados modulados por el agonista del receptor Y2 del neuropéptido Y (NPY).The invention provides variants of the PYY3-36 peptide and its pegylated derivatives and compositions and methods useful in the treatment of states modulated by the Y2 receptor neuropeptide agonist (NPY).

UY29711A 2006-01-27 2006-07-31 SMALL AGONISTS AND THEIR USES UY29711A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW095103474A TWI310038B (en) 2005-02-04 2006-01-27 Pyy agonists and uses thereof
CL2006000186 2006-01-27
PCT/IB2006/000270 WO2006082517A1 (en) 2005-02-04 2006-01-30 Pyy agonists and uses thereof

Publications (1)

Publication Number Publication Date
UY29711A1 true UY29711A1 (en) 2007-08-31

Family

ID=46969902

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29711A UY29711A1 (en) 2006-01-27 2006-07-31 SMALL AGONISTS AND THEIR USES

Country Status (7)

Country Link
AR (1) AR054602A1 (en)
HN (1) HN2006027890A (en)
NL (1) NL1032266C2 (en)
PE (1) PE20070997A1 (en)
SV (1) SV2006002635A (en)
UY (1) UY29711A1 (en)
WO (1) WO2007085887A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
KR101059602B1 (en) 2005-12-07 2011-08-25 에프. 호프만-라 로슈 아게 Neuropeptide 2 Receptor Agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212985A (en) * 2001-09-24 2005-08-30 Imp College Innovations Ltd Use of pyy or an agonist in the preparation of medicaments for treating disorders associated with overweight
WO2004089279A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
PA8660701A1 (en) * 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists

Also Published As

Publication number Publication date
PE20070997A1 (en) 2007-11-30
NL1032266C2 (en) 2007-10-09
HN2006027890A (en) 2010-06-09
WO2007085887A1 (en) 2007-08-02
NL1032266A1 (en) 2007-07-30
SV2006002635A (en) 2010-02-04
AR054602A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
DOP2006000025A (en) SMALL AGONISTS AND THEIR USES
CL2009000171A1 (en) Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression.
SMT201300093B (en) Lyophilized recombinant vwf formulations
LU91989I2 (en) BYDUREON
ECSP088759A (en) PHARMACEUTICAL COMPOSITIONS
ATE469895T1 (en) CGRP RECEPTOR ANTAGONISTS
CR9428A (en) METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
CL2012001722A1 (en) Compounds derived from 3-hydroxy-5-arylisothiazole, agonists of receptor 40 coupled to protein g (gpr40); pharmaceutical composition comprising them; and method for the treatment or prevention of diabetes.
CL2007002649A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES 2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL] -4-FLUORO- BENZONITRILE; AND USE FOR THE TREATMENT OF DIABETES.
CL2011002942A1 (en) Compounds derived from 2,4-diamino-pyrimidine, toll-7 (tlr7) receptor agonists; pharmaceutical composition; and its use for the treatment of cancer.
EA201290964A1 (en) Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
CL2007001749A1 (en) Compound derived from 2-arylamino-4- (heterocycle) aminopyrimidine, c-alpha protein kinase inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of diabetes, cancer, coronary heart disease, atherosclerosis, among others.
ECSP088315A (en) MODULATORS OF HEXAHYDRO-CYCLLOOCTIL PIRAZOL CANNABINOIDE
CR20110202A (en) ANTAGONISTS OF THE VIA HEDGEHOG OF FTALAZINA DISUSTITUIDA
CL2008003546A1 (en) Pyridine derived compounds; preparation procedure; pharmaceutical composition of said compounds; and use in the treatment and / or prophylaxis of type I and / or type II diabetes mellitus.
ES2530670T3 (en) Anti-FGF23 antibody and pharmaceutical composition comprising the same
CL2007002769A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; OBTAINING PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DIABETES.
CL2009000904A1 (en) Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
PA8748501A1 (en) USE OF LXR AGONISTS FOR THE TREATMENT OF OSTEOARTHRITIS
ATE519498T1 (en) COMBINATION OF SOMATOSTATIN ANALOGAS OF DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES
CL2008000091A1 (en) COMPOUNDS DERIVED FROM PIRIDINA, INHIBITORS OF THE P2Y12 RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE PLAQUETARY AGREGATION DISORDER.
UY29711A1 (en) SMALL AGONISTS AND THEIR USES
EA200970338A2 (en) HUMAN ERO RECEPTOR AGONISTS, COMPOSITIONS, METHODS AND APPLICATIONS FOR THE PREVENTION OR TREATMENT OF CONDITIONS RELATED TO GLUTOSE INTOLERANCE
EA200802104A1 (en) APPLICATION OF COMPOSITIONS CONTAINING ANTAGONISTS OF CAPPA-OPIOID RECEPTORS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
HN2006004322A (en) SMALL AGONISTS AND THEIR USES

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160830